Home/Biosimilar Atlas/Companies/mAbxience

mAbxience

Biosimilar developer, Spain. 2 development products across 2 molecules: bevacizumab, denosumab.

First approval in the Atlas: Mar 2021, Alymsys, bevacizumab (EMA)
FDAproducts approved2
EMAproducts approved2
MHRAproducts approved2
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Connections
2molecules2products3 of 7markets2candidates in trials8companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
BevacizumabAlymsys / Oyavas MB02Apr 2022Mar 2021MHRA····3/7
DenosumabBoncresa / Oziltus / Denbrayce / Izamby MB09Dec 2025Jun 2025MHRA····3/7

Month shown is the first approval or registration of that product in that market.

In development

ClinicalTrials.gov lists eleven comparative trials sponsored by mAbxience for four molecules: bevacizumab, denosumab, etanercept, rituximab. Candidates without an approval yet in the seven markets: MB04, RTXM83.

MoleculeCandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionIn the AtlasRegistry record
BevacizumabMB02mAbxienceAvastinPhase 1Comparative PKCompletedAug 2019Dec 2019Alymsys / OyavasNCT04238650
BevacizumabMB02mAbxienceAvastinPhase 1Comparative PKCompletedDec 2017May 2019Alymsys / OyavasNCT03293654
BevacizumabMB02mAbxienceAvastinPhase 3Comparative efficacyCompletedFeb 2018Jul 2019Alymsys / OyavasNCT03296163
BevacizumabMB02mAbxienceAvastinPhase 1Comparative PKCompletedJan 2021Aug 2021Alymsys / OyavasNCT04408989
BevacizumabBEVZ92mAbxienceAvastinPhase 1Comparative PKCompletedOct 2014Oct 2015Alymsys / OyavasNCT02069704
BevacizumabMB02mAbxienceAvastinPhase 1Comparative PKCompletedSep 2019Mar 2020Alymsys / OyavasNCT04238663
DenosumabMB09mAbxienceProliaPhase 3Comparative efficacyCompletedMar 2022Dec 2023Boncresa / Oziltus / Denbrayce / IzambyNCT05338086
DenosumabMB09mAbxienceXgevaPhase 1Comparative PKCompletedMar 2022Mar 2023Boncresa / Oziltus / Denbrayce / IzambyNCT05299073
EtanerceptMB04mAbxienceEnbrelPhase 1Comparative PKCompletedMar 2024May 2025no approval in the seven marketsNCT06392074
EtanerceptMB04mAbxienceEnbrelPhase 3Comparative efficacyRecruitingOct 2024Oct 2025no approval in the seven marketsNCT06596772
RituximabRTXM83mAbxienceMabTheraPhase 3Comparative efficacyCompletedMay 2013May 2016no approval in the seven marketsNCT02268045

Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.

Companies on the same molecules

Developers whose portfolios overlap most with mAbxience, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

ApotexTwo shared molecules: bevacizumab, denosumab3 molecules in its portfolioBiocon BiologicsTwo shared molecules: bevacizumab, denosumab9 molecules in its portfolioCelltrionTwo shared molecules: bevacizumab, denosumab10 molecules in its portfolioEnzene BiosciencesTwo shared molecules: bevacizumab, denosumab6 molecules in its portfolioHeteroTwo shared molecules: bevacizumab, denosumab5 molecules in its portfolioIntas PharmaceuticalsTwo shared molecules: bevacizumab, denosumab12 molecules in its portfolioReliance Life SciencesTwo shared molecules: bevacizumab, denosumab14 molecules in its portfolioSamsung BioepisTwo shared molecules: bevacizumab, denosumab10 molecules in its portfolio

Chronology

Compare mAbxience with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.